The FDA found that the Olympus technology visualized NMIBS lesions in 17 percent more patient when compared with white light, 24 percent additional tumor and 28 percent additional carcinoma in situ.
The new technology can be used in both the office and operating room.
More articles on FDA clearances:
FDA clears Third Eye Panoramic device for colonoscopy
5 GI/endoscopy devices receive FDA 510(k) clearance in September
3 GI/endoscopy devices receive FDA 510(k) clearance in October
